Category Archives: News
A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
Neihulizumab (ALTB-168) is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), and leads to downregulation of activated T-cells. Early-phase trials of neihulizumab have suggested a benefit in patients with immune conditions… Continue reading
Posted in News
Comments Off on A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
LONGITUDINAL COMPRESSION THERAPY FOR SMALL BOWEL STRICTURE CROHN’S DISEASE: DURABLE RESOLUTION IN SWINE MODEL
Small bowel stricture is common in Crohn’s disease (CD), both de novo and after resection. With all standard treatments having high recurrence rates, CD patients would benefit greatly from a novel and highly durable non-surgical intervention. We report… Continue reading
Posted in News
Comments Off on LONGITUDINAL COMPRESSION THERAPY FOR SMALL BOWEL STRICTURE CROHN’S DISEASE: DURABLE RESOLUTION IN SWINE MODEL
POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON
The clinical remission rate in moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) has plateaued at ∼15-20% despite the approval of multiple therapeutics. Research has shown that an inadequate amount of drug at the disease site in the c… Continue reading
Posted in News
Comments Off on POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON
AN OBSERVATIONAL STUDY DEMONSTARTING THE MEASUREMENT, CHARACTERIZATION AND VALIDATION OF EXPRESSIONS OF CALPROTECTIN IN HUMAN SWEAT THROUGH A SWEAT WEARABLE
Inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative colitis (UC) are typically characterized by chronic episodes of inflammation within and through the gastrointestinal (GI) tract. In many inflammatory conditions including … Continue reading
Posted in News
Comments Off on AN OBSERVATIONAL STUDY DEMONSTARTING THE MEASUREMENT, CHARACTERIZATION AND VALIDATION OF EXPRESSIONS OF CALPROTECTIN IN HUMAN SWEAT THROUGH A SWEAT WEARABLE
USING R TO ADVANCE PATIENT-CENTRIC RESEARCH IN THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT
IBD Plexus is a data exchange platform that houses four cohorts, including The Study of a Prospective Adult Research Cohort with IBD (SPARC IBD). SPARC IBD is a multicentered, longitudinal cohort that follows patients through their standard of care. In… Continue reading
Posted in News
Comments Off on USING R TO ADVANCE PATIENT-CENTRIC RESEARCH IN THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT
MORTALITY AND MORBIDITY DIFFERENCE IN GERIATRICS PATIENTS HOSPITALIZED FOR INFLAMMATORY BOWEL DISEASE: POPULATION-BASED AGE-STRATIFIED RETROSPECTIVE STUDY
Given the increase in prevalence of Inflammatory Bowel Disease (IBD) worldwide and the increase in general population life expectancy, it is expected to for IBD to be more prevalent disorder among elderly patients. However, the mortality and outcomes o… Continue reading
Posted in News
Comments Off on MORTALITY AND MORBIDITY DIFFERENCE IN GERIATRICS PATIENTS HOSPITALIZED FOR INFLAMMATORY BOWEL DISEASE: POPULATION-BASED AGE-STRATIFIED RETROSPECTIVE STUDY
THIRD TIME’S THE CHARM? INDICATIONS AND LONG-TERM OUTCOMES AFTER REDO-REDO ILEAL POUCH ANAL ANASTOMOSIS
Pouch failure after redo ileal pouch anal anastomosis (IPAA) occurs in 20-40% of cases. The decision to offer a second redo procedure to maintain intestinal continuity is controversial, and scarce evidence exists regarding long-term pouch survival and … Continue reading
Posted in News
Comments Off on THIRD TIME’S THE CHARM? INDICATIONS AND LONG-TERM OUTCOMES AFTER REDO-REDO ILEAL POUCH ANAL ANASTOMOSIS
REAL-WORLD USTEKINUMAB PERSISTENCE IN PATIENTS WITH ULCERATIVE COLITIS ATTAINING THE MAINTENANCE PHASE
Sustained use of biologics and small molecule/advanced therapy has proven to be effective for controlling disease activity in ulcerative colitis (UC). The anti-interleukin agent ustekinumab was recently approved for UC in 2019. This study aimed to desc… Continue reading
Posted in News
Comments Off on REAL-WORLD USTEKINUMAB PERSISTENCE IN PATIENTS WITH ULCERATIVE COLITIS ATTAINING THE MAINTENANCE PHASE
DEMOCRATIC DELIBERATION TO ASSESS VETERAN PREFERENCES FOR BIOSIMILAR MEDICATION SWITCHING FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN A RESOURCE CONSCIOUS SETTING
To optimize care while being resource conscious, the Veterans Health Administration (VHA) must develop equitable policies that incorporate Veterans’ values and beliefs. Switching patients with Inflammatory Bowel Disease (IBD) from biologic medications … Continue reading
Posted in News
Comments Off on DEMOCRATIC DELIBERATION TO ASSESS VETERAN PREFERENCES FOR BIOSIMILAR MEDICATION SWITCHING FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN A RESOURCE CONSCIOUS SETTING
THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD) that causes relapsing and remitting inflammation in the colon and rectum. Numerous treatment options are available for patients with UC including biologics and small molecule inhi… Continue reading
Posted in News
Comments Off on THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS